Hundreds of Genes Linked to Moles Point to Melanoma Fixes

What if the tiny spots on your skin were whispering secrets about cancer risks? Researchers at QIMR Berghofer have just decoded part of that whisper, revealing a vast genetic landscape that ties mole formation to melanoma in ways that go beyond sun exposure and skin tone.

In a paper published in Nature Communications, the team analyzed genetic information from more than 85,000 people of European ancestry and pinpointed 24 previously unknown DNA regions associated with mole count. That jump from five regions in a 2018 study to dozens today is not incremental. It is a leap that expands a list of candidate genes to more than 250, each one now a lead for labs hunting the biology behind moles and malignant transition.

Moles and melanoma share an origin: the pigment-producing melanocyte. Most of the time, these cells multiply then stop, leaving harmless spots. Sometimes they do not stop. Roughly a third of melanomas arise from existing moles, and a high mole burden remains one of the clearest predictors of risk. Genetics, it turns out, plays a major role in who ends up with many moles.

Study authors: Shanika Jayasinghe and A/Prof Matthew Law. 

The new study highlights pathways you would not expect to find by looking at sunburn history alone. Several implicated genes sit inside immune-related networks that normally keep cell growth in check. Others are connected to cell proliferation pathways seen in breast, prostate, and brain cancers. One standout is SIKE1, a gene involved in antiviral immune response; when it malfunctions, researchers say, the immune system might fail to spot and clear melanocytes that are growing abnormally — a potential early step toward melanoma.

Why does that matter? Because if these pathways can be blocked, modified, or nudged back into balance, they offer fresh targets for prevention and therapy. Current immunotherapies have transformed outcomes for many patients, yet about half of late-stage melanoma cases do not respond. New molecular entry points could broaden the toolkit clinicians use to prevent progression or treat disease that resists existing drugs.

To turn genomic signals into clinical tools, the authors built a polygenic risk score for what they call 'moliness' — a composite measure of inherited variants that predispose someone to a high mole count. In future screening programs this kind of score might help flag people who would benefit from more intensive dermatological monitoring, long before a lesion becomes dangerous.

The research team plans to scale up, mining larger datasets to find more genetic regions and to test whether existing medications can be repurposed against the newly revealed pathways. Their work builds on decades of genetics research at QIMR Berghofer, combining twin studies, genome-wide analyses, and large population cohorts such as the QSkin Sun and Health Study.

Discoveries like these change the question from how to live with sun risk to how we might intercept cancer biology earlier and more precisely. The next moves are ambitious: validate the genes, map the mechanisms, and run trials that test whether intervening on these pathways truly prevents melanoma. Watch this space — the dots on your skin may tell a story that saves lives.